Jumping on the Vertebroplasty Bandwagon

With estimates for the number of current procedures now at 35,000-40,000 and growing, established spinal orthopedics companies are beginning to cash in on the rapidly growing use of bone cements and cement delivery systems for vertebral compression fracture repair, or vertebroplasty. To date, Cook Group and Medtronic Sofamor Danek have been supplying the majority of kits. Danek also recently began selling a PMMA resin tailored for vertebroplasty, and Stryker has indicated that it too has its sights set on the vertebroplasty opportunity: it is currently reformulating one of its existing cement products for use in vertebroplasty. That Stryker and Danek-- both industry leaders in orthopedics - are positioning themselves in this market suggests that it may be the next hot area in spine.

Just a few months ago, medical device industry analysts were estimating the number of current US vertebroplasties—a rapid, percutaneous technique for repairing spinal compression fractures by injecting bone cement into the vertebral body—to be around 12,000-20,000 annually. The number appears to be much higher, however—closer to 35,000-40,000, and growing. With at least 200,000 potential patients in the US alone, principally elderly, osteoporotic individuals with persistent pain that is currently treated with narcotics and immobilization, and spurred by consumer demand for an alternative, the near-term market opportunity for the sale of bone cement and delivery systems appears to be at least several hundred million dollars.

Although companies and practitioners are each angling for a piece of the action, getting a handle on the scope of...

More from Innovation

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By 

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.